Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alimera To Resubmit Iluvien With No New Studies

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA has twice rebuffed Alimera’s marketing application for the intravitreal insert, which releases a corticosteroid to treat chronic diabetic macular edema, citing a bad risk/benefit balance. But after meeting with the agency in the second quarter, the company is confident a reanalysis of pivotal data will satisfy the agency.

You may also be interested in...

Alimera’s Diabetic Macular Edema Drug Iluvien Gets Third FDA Rejection

FDA cites concerns about safety and manufacturing in third “complete response” letter for intravitreal implant Iluvien in diabetic macular edema. Agency requests new trial and an advisory committee meeting in early 2014.

Alimera’s Iluvien Suffers Same Demise As Lucentis; NICE Rejects For DME

Triumphant in Europe at the regulatory stage, Alimera finds that health technology assessment is a different ball game, as NICE turns down Iluvien for diabetic macular edema on two counts.

Financings Of The Fortnight: Bluebird Spots Brighter Skies For Gene Therapy Investment

Plus news on recent financings by California Institute for Regenerative Medicine, Alimera Sciences, Durata Therapeutics and CoDa Therapeutics.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts